Table 2.

Baseline information of included studies for glioma grading

Reference	Year	Country	Design	Specimens No.	Patients No.	Age, yr		M/F	Test	Prior treatment	Occurrence	Gold Standard	Parameter	Cut-off
						Meana	Median
Fueger et al. [12]	2010	US	17 Prospective+ 42 Retrospective	59	59 (22b)	–	44.5	13/9	PET or PET/CT	With (Sx + CT/RT) or without	New	Histo	SUVmax	2.72
Nioche et al. [32]	2013	France	Prospective	33	33	51 ± 16	51	28/5	PET/CT	With (Sx + CT/RT) or without	20 New+ 13 Recur	Histo	SUVmean	2.2
Pafundi et al. [24]	2013	US	Prospective	23	10 (9b)	42.9 ± 19.2	–	8/1	PET/CT	With or without	7 New+ 2 Recur	Histo	SUVmax T/SUVmean N	2.0
Janvier et al. [13]	2015	France	Retrospective	31	31	36.8 ± 12.1	–	13/18	PET	With (Sx/CT/RT) or without	25 New+ 6 Recur	Histo+Radio+follow-up	SUVmean T/N	1.33
Bund et al. [33]	2017	France	Prospective	53	53	38	–	23/30	PET/CT	Without	New	Histo	SUVmax T/N	2.16
Morana et al. [34]	2017	Italy	Retrospective	26	26	10.2 ± 4.6	9.5	15/11	PET	Without	New	Histo	SUVmax T/S	0.90
Patel et al. [35]	2018	US	Prospective	45	45	46.4 ± 16.2	–	22/23	PET	Without	New	Histo	SUVmax T/N	1.7

M, male; F, female; Sx, surgery; CT, chemotherapy; RT, radiation therapy; New, newly-diagnosed; Recur, recurrent; Histo, histopathology; SUV, standardized uptake value; Radio, radiology; T, tumor; N, normal; S, Striatum

^aMean age is expressed as mean ± standard deviation

^bPatients that are finally included in the quantitative analysis by authors